Leerink Partnrs Brokers Decrease Earnings Estimates for SPRY

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) – Research analysts at Leerink Partnrs lowered their FY2027 earnings per share estimates for shares of ARS Pharmaceuticals in a note issued to investors on Wednesday, November 13th. Leerink Partnrs analyst R. Ruiz now expects that the company will earn $0.55 per share for the year, down from their previous estimate of $0.60. The consensus estimate for ARS Pharmaceuticals’ current full-year earnings is ($0.64) per share.

A number of other equities analysts also recently commented on the stock. Raymond James raised shares of ARS Pharmaceuticals from an “outperform” rating to a “strong-buy” rating and boosted their price objective for the stock from $18.00 to $22.00 in a research note on Tuesday, August 13th. Leerink Partners raised their price objective on ARS Pharmaceuticals from $21.00 to $25.00 and gave the company an “outperform” rating in a research report on Friday, September 20th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $30.00 target price on shares of ARS Pharmaceuticals in a report on Tuesday, October 8th. Finally, William Blair upgraded shares of ARS Pharmaceuticals to a “strong-buy” rating in a report on Friday, August 30th. Four research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat.com, ARS Pharmaceuticals has a consensus rating of “Buy” and a consensus target price of $24.00.

ARS Pharmaceuticals Price Performance

NASDAQ:SPRY opened at $14.01 on Friday. ARS Pharmaceuticals has a 1-year low of $4.28 and a 1-year high of $18.51. The company has a 50-day moving average of $14.63 and a 200 day moving average of $11.73. The firm has a market cap of $1.36 billion, a PE ratio of -27.47 and a beta of 0.90.

Insiders Place Their Bets

In other ARS Pharmaceuticals news, insider Sarina Tanimoto sold 100,000 shares of ARS Pharmaceuticals stock in a transaction on Tuesday, October 15th. The shares were sold at an average price of $14.88, for a total value of $1,488,000.00. Following the completion of the transaction, the insider now owns 1,298,499 shares of the company’s stock, valued at approximately $19,321,665.12. The trade was a 7.15 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, major shareholder James E. Flynn sold 528,456 shares of the business’s stock in a transaction that occurred on Monday, November 11th. The shares were sold at an average price of $18.04, for a total value of $9,533,346.24. Following the completion of the sale, the insider now owns 5,274,735 shares of the company’s stock, valued at $95,156,219.40. This trade represents a 9.11 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 1,584,351 shares of company stock valued at $24,152,378. Insiders own 40.10% of the company’s stock.

Hedge Funds Weigh In On ARS Pharmaceuticals

Hedge funds and other institutional investors have recently modified their holdings of the business. nVerses Capital LLC acquired a new position in ARS Pharmaceuticals in the third quarter valued at approximately $30,000. Russell Investments Group Ltd. acquired a new stake in shares of ARS Pharmaceuticals in the first quarter valued at approximately $60,000. Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in shares of ARS Pharmaceuticals by 151.7% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 7,419 shares of the company’s stock valued at $63,000 after purchasing an additional 4,472 shares during the period. Principal Financial Group Inc. acquired a new position in ARS Pharmaceuticals during the 2nd quarter worth approximately $87,000. Finally, Paloma Partners Management Co acquired a new position in ARS Pharmaceuticals during the first quarter worth about $103,000. 68.16% of the stock is owned by hedge funds and other institutional investors.

ARS Pharmaceuticals Company Profile

ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers.